(ADCT) ADC Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 480m USD | Total Return: 210.7% in 12m

ZYNLONTA, CD22-ADC, ADCT-602, Claudin-6, NaPi2b
Total Rating 49
Safety 36
Buy Signal -0.65
Biotechnology
Industry Rotation: +0.2
Market Cap: 480M
Avg Turnover: 2.63M USD
ATR: 6.90%
Peers RS (IBD): 53.4
Risk 5d forecast
Volatility80.3%
Rel. Tail Risk-12.0%
Reward TTM
Sharpe Ratio1.80
Alpha154.92
Character TTM
Beta1.938
Beta Downside1.078
Drawdowns 3y
Max DD82.40%
CAGR/Max DD0.21
EPS (Earnings per Share) EPS (Earnings per Share) of ADCT over the last years for every Quarter: "2021-03": -0.46, "2021-06": -0.96, "2021-09": -0.93, "2021-12": -0.45, "2022-03": -0.22, "2022-06": -0.84, "2022-09": -0.65, "2022-12": -0.3, "2023-03": -0.74, "2023-06": -0.58, "2023-09": -0.58, "2023-12": -1.03, "2024-03": -0.56, "2024-06": -0.38, "2024-09": -0.42, "2024-12": -0.25, "2025-03": -0.36, "2025-06": -0.25, "2025-09": -0.19, "2025-12": -0.04,
EPS CAGR: 5.26%
EPS Trend: 54.8%
Last SUE: 1.12
Qual. Beats: 1
Revenue Revenue of ADCT over the last years for every Quarter: 2021-03: 51.9, 2021-06: 3.76, 2021-09: 13.147, 2021-12: 17.01, 2022-03: 46.498, 2022-06: 17.291, 2022-09: 76.321, 2022-12: 69.798, 2023-03: 18.992, 2023-06: 19.283, 2023-09: 14.493, 2023-12: 16.79, 2024-03: 18.053, 2024-06: 17.41, 2024-09: 18.464, 2024-12: 16.91, 2025-03: 23.033, 2025-06: 18.839, 2025-09: 16.427, 2025-12: 23.058,
Rev. CAGR: -17.06%
Rev. Trend: -48.6%
Last SUE: 0.35
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Share dilution 42.6% YoY - potential capital distress

Interest Coverage Ratio -2.1 is critical

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ADCT ADC Therapeutics

ADC Therapeutics SA (NYSE: ADCT) commercializes an antibody-drug-conjugate (ADC) platform focused on hematologic malignancies and solid tumors, with its lead product ZYNLONTA (loncastuximab tesirine) approved in the U.S., EU, and China for relapsed/refractory diffuse large B-cell lymphoma after ≥ 2 prior therapies.

Recent data show ZYNLONTA generated approximately $45 million in worldwide revenue in FY 2023, while the company reported a cash balance of $150 million at the end of Q1 2024, supporting ongoing Phase 3 LOTIS-5 and Phase 1b LOTIS-7 trials that aim to move the drug into earlier lines of DLBCL and into indolent lymphomas such as follicular and marginal-zone lymphoma. In addition, ADCT’s CD-22 ADC (ADCT-602) is enrolling in a Phase 1/2 investigator-initiated trial for refractory B-cell ALL, and its pre-clinical pipeline targets Claudin-6, NaPi2b, PSMA, and ASCT2.

The ADC sector is benefitting from a projected CAGR of roughly 15 % through 2030, driven by rising demand for targeted oncology therapies and favorable reimbursement trends in major markets. For a deeper dive into ADCT’s valuation and risk profile, you might explore the analysis on ValueRay.

Headlines to Watch Out For
  • Zynlonta sales growth drives revenue expansion
  • Clinical trial outcomes impact future product approvals
  • Regulatory approvals expand market access for therapies
  • Competition from new cancer treatments pressures market share
  • Research and development expenses affect profitability
Piotroski VR‑10 (Strict) 1.5
Net Income: -142.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.44 > 0.02 and ΔFCF/TA -5.04 > 1.0
NWC/Revenue: 290.3% < 20% (prev 320.3%; Δ -30.05% < -1%)
CFO/TA -0.44 > 3% & CFO -141.2m > Net Income -142.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.37 > 1.5 & < 3
Outstanding Shares: last quarter (150.3m) vs 12m ago 42.61% < -2%
Gross Margin: 90.57% > 18% (prev 0.92%; Δ 8.97k% > 0.5%)
Asset Turnover: 25.22% > 50% (prev 22.00%; Δ 3.22% > 0%)
Interest Coverage Ratio: -2.10 > 6 (EBITDA TTM -106.5m / Interest Expense TTM 51.6m)
Altman Z'' -15.00
A: 0.73 (Total Current Assets 306.3m - Total Current Liabilities 70.2m) / Total Assets 323.1m
B: -5.06 (Retained Earnings -1.64b / Total Assets 323.1m)
C: -0.34 (EBIT TTM -108.4m / Avg Total Assets 322.6m)
D: -3.19 (Book Value of Equity -1.63b / Total Liabilities 509.0m)
Altman-Z'' Score: -17.32 = D
Beneish M 1.00
DSRI: 1.25 (Receivables 29.1m/20.3m, Revenue 81.4m/70.8m)
GMI: 1.01 (GM 90.57% / 91.60%)
AQI: 13.32 (AQ_t 0.05 / AQ_t-1 0.00)
SGI: 1.15 (Revenue 81.4m / 70.8m)
TATA: -0.00 (NI -142.6m - CFO -141.2m) / TA 323.1m)
Beneish M-Score: 4.59 (Cap -4..+1) = D
What is the price of ADCT shares? As of April 10, 2026, the stock is trading at USD 3.76 with a total of 630,047 shares traded.
Over the past week, the price has changed by -0.53%, over one month by -11.11%, over three months by +2.73% and over the past year by +210.74%.
Is ADCT a buy, sell or hold? ADC Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ADCT.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ADCT price?
Analysts Target Price 8.2 118.1%
ADC Therapeutics (ADCT) - Fundamental Data Overview as of 06 April 2026
P/S = 5.9027
P/B = 3.4239
Revenue TTM = 81.4m USD
EBIT TTM = -108.4m USD
EBITDA TTM = -106.5m USD
Long Term Debt = 112.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.00m USD (from shortTermDebt, last quarter)
Debt = 439.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 177.7m USD (from netDebt column, last quarter)
Enterprise Value = 657.9m USD (480.2m + Debt 439.0m - CCE 261.3m)
Interest Coverage Ratio = -2.10 (Ebit TTM -108.4m / Interest Expense TTM 51.6m)
EV/FCF = -4.65x (Enterprise Value 657.9m / FCF TTM -141.4m)
FCF Yield = -21.50% (FCF TTM -141.4m / Enterprise Value 657.9m)
 FCF Margin = -173.9% (FCF TTM -141.4m / Revenue TTM 81.4m)
 Net Margin = -175.3% (Net Income TTM -142.6m / Revenue TTM 81.4m)
Gross Margin = 90.57% ((Revenue TTM 81.4m - Cost of Revenue TTM 7.67m) / Revenue TTM)
Gross Margin QoQ = 84.50% (prev 92.68%)
Tobins Q-Ratio = 2.04 (Enterprise Value 657.9m / Total Assets 323.1m)
Interest Expense / Debt = 2.96% (Interest Expense 13.0m / Debt 439.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -85.6m (EBIT -108.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.37 (Total Current Assets 306.3m / Total Current Liabilities 70.2m)
 Debt / Equity = -2.36 (negative equity) (Debt 439.0m / totalStockholderEquity, last quarter -185.8m)
 Debt / EBITDA = -1.67 (negative EBITDA) (Net Debt 177.7m / EBITDA -106.5m)
 Debt / FCF = -1.26 (negative FCF - burning cash) (Net Debt 177.7m / FCF TTM -141.4m)
 Total Stockholder Equity = -215.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.22% (Net Income -142.6m / Total Assets 323.1m)
 RoE = 66.23% (negative equity) (Net Income TTM -142.6m / Total Stockholder Equity -215.4m)
 RoCE = 105.3% (negative capital employed) (EBIT -108.4m / Capital Employed (Equity -215.4m + L.T.Debt 112.5m))
 RoIC = 85.09% (negative operating profit) (NOPAT -85.6m / Invested Capital -100.6m)
 WACC = 7.81% (E(480.2m)/V(919.2m) * Re(12.80%) + D(439.0m)/V(919.2m) * Rd(2.96%) * (1-Tc(0.21)))
Discount Rate = 12.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 35.15%
 [DCF] Fair Price = unknown (Cash Flow -141.4m)
 EPS Correlation: 54.80 | EPS CAGR: 5.26% | SUE: 1.12 | # QB: 1
Revenue Correlation: -48.59 | Revenue CAGR: -17.06% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.19 | Chg7d=+0.005 | Chg30d=+0.067 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=-0.80 | Chg7d=+0.006 | Chg30d=+0.275 | Revisions Net=+4 | Growth EPS=+28.6% | Growth Revenue=-1.7%
EPS next Year (2027-12-31): EPS=-0.64 | Chg7d=+0.126 | Chg30d=+0.048 | Revisions Net=-1 | Growth EPS=+20.5% | Growth Revenue=+66.7%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle